Biotechnology
Oncotelic Therapeutics Exemplifies Biotech Sector's Shift Toward Pipeline-Driven Valuation
Oncotelic Therapeutics illustrates how biotechnology companies are increasingly being valued based on clinical progress and pipeline assets rather than traditional metrics, representing a fundamental shift in sector valuation practices.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Biotech Valuations Shift as Scientific Progress Gains Financial Recognition
The biotechnology industry is undergoing a transformation where scientific advancement is increasingly quantified as financial assets through fair-value accounting, with companies like Oncotelic Therapeutics demonstrating how clinical progress translates to tangible economic value.
Oncotelic Therapeutics Reports $249 Million Net Income for FY 2025 Driven by Joint Venture Valuation
Oncotelic Therapeutics announced a dramatic financial turnaround with $249 million net income for fiscal year 2025, primarily due to a non-cash gain from its GMP Biotechnology joint venture valuation, signaling potential growth in its oncology and COVID-19 drug pipeline.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Oncotelic Therapeutics Featured in Editorial Highlighting Biotech's Shift Toward Science-Driven Asset Valuation
A BioMedWire editorial highlights how biotechnology companies like Oncotelic Therapeutics are increasingly seeing scientific progress translate into measurable financial value through fair-value accounting frameworks, with Oncotelic's 45% stake in GMP Bio valued at over $1 billion.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Formycon to Announce 2025 Financial Results and Participate in Key Investor Conferences
Formycon AG will release its 2025 financial results and provide a 2026 outlook during an April conference call, while planning participation in multiple international investor conferences to showcase its biosimilar pipeline amid growing market opportunities.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Trial Progress and Promising Biomarker Data
Annovis Bio reports significant progress in its Phase 3 Alzheimer's trial with full site activation and promising biomarker data showing buntanetap's disease-modifying potential, positioning the company for potential regulatory submission.
GeoVax Advances Vaccine Programs Amid Global Health Crises Despite Financial Losses
GeoVax Labs reported significant progress in its mpox, COVID-19, and cancer vaccine programs during Q3 2025, positioning the company as a key player in addressing urgent public health needs while navigating financial challenges.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Pipeline
NanoViricides has completed a $6 million capital raise to fund development of its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Quantumzyme Expands AI Enzyme Platform to Transform Pharmaceutical Manufacturing
Quantumzyme Corp. is expanding its AI-driven enzyme engineering platform to develop sustainable manufacturing processes for multiple high-volume pharmaceutical ingredients, potentially reducing hazardous waste and carbon emissions in the $300 billion global API market.
Wireless Brain Implants Could Revolutionize Neurological Treatment Without Surgery
MIT researchers have developed microscopic wireless implants that can navigate to brain tissue autonomously, potentially eliminating the need for surgery in treating tumors and neurological conditions.
GeoVax Emphasizes Vaccine Innovation and Trust Building on World Immunization Day
GeoVax Labs is advancing next-generation multi-antigen vaccines and U.S. manufacturing capabilities to address declining public confidence in newer vaccines while protecting vulnerable populations.
CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Lantern Pharma to Host Q3 2025 Results Webcast, Highlighting AI-Driven Oncology Pipeline
Lantern Pharma will review its third-quarter 2025 financial results and AI platform developments during a November webcast, showcasing how artificial intelligence is accelerating cancer drug discovery and development.
Datavault AI Grants Scilex Exclusive License for AI-Driven Biotech Exchange Platform
Datavault AI has granted Scilex Holding Company exclusive worldwide rights to deploy its AI technology for tokenizing and trading biotech assets, potentially unlocking a $2 trillion market opportunity in pharmaceutical data exchange.
MIT and Harvard Researchers Develop Enhanced Natural Killer Cell Therapy for Cancer Treatment
Researchers from MIT and Harvard Medical School have engineered modified natural killer cells that show promising results in fighting cancer while avoiding immune system rejection, potentially transforming cancer immunotherapy approaches.
BioUtah Announces 2025 Life Sciences Award Winners Recognizing Utah's Healthcare Innovation Leaders
BioUtah will honor five distinguished individuals and companies at the 2025 Mayer Brown Utah Life Sciences Summit for their transformative contributions to healthcare innovation and economic growth in Utah's life sciences sector.
Ocumetics Reports Promising Early Results in First Human Lens Implant Study
Ocumetics Technology Corp. announced encouraging one-month vision results from its first human clinical study of an accommodating intraocular lens, showing potential to transform cataract treatment and reduce dependence on corrective lenses.
Quantumzyme Validates Sustainable Ibuprofen Manufacturing Process in Peer-Reviewed Publication
Quantumzyme Corp. has published research validating its enzymatic process for sustainable ibuprofen production, representing a significant advancement toward greener pharmaceutical manufacturing with reduced environmental impact.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
GeoVax Relocates Headquarters and Labs to Atlanta Area to Fuel Growth and Pipeline Advancement
GeoVax Labs is relocating its corporate headquarters and laboratory operations to new Atlanta-area facilities, positioning the clinical-stage biotechnology company for accelerated growth, late-stage development, and future commercialization of its cancer and infectious disease therapies.
Quantum BioPharma Announces Private Placement to Strengthen Voting Control and Fund Operations
Quantum BioPharma Ltd. is conducting a $750 private placement that will significantly increase voting control for its key executives while providing working capital for its neurodegenerative and metabolic disorder treatments.
BIO CEO Warns U.S. Could Lose Biotech Leadership to China Within Two Years
GeoVax Labs calls for urgent policy action following Biotechnology Innovation Organization CEO John Crowley's warning that China could overtake U.S. biotech leadership within two years, highlighting the need for vaccine platform diversity, onshoring manufacturing, and protecting immunocompromised populations.
Helix BioPharma Narrows Losses Amid Strategic Shift to Lung Cancer Focus
Helix BioPharma reported reduced financial losses for fiscal 2025 while implementing a strategic pivot to focus exclusively on developing its L-DOS47 treatment for non-small cell lung cancer in combination with immunotherapy.